加载中
NASDAQHealthcareMedical - Devices
最新数据
US$7.86
−US$0.29 · -3.56%
enVVeno Medical Corporation, based in Irvine, California, is a medical device firm founded in 1999 that is currently in its clinical development phase. The company's primary objective is to pioneer advanced bioprosthetic, tissue-engineered solutions intended to significantly elevate the existing standards of care for patients suffering from venous conditions. Their flagship product is the VenoValve, a specialized replacement venous valve developed for the management of chronic venous insufficiency. This device requires an open surgical procedure for implantation, which involves making a 5-to-6-inch incision in the patient's upper thigh to facilitate placement into the femoral vein. In addition to the VenoValve, enVVeno Medical is actively developing the enVVe system. This innovative system represents a non-surgical, transcatheter approach to venous valve replacement, comprising the enVVe valve itself, a dedicated delivery mechanism, and various supplementary accessories. The company previously operated under the name Hancock Jaffe Laboratories, Inc., before officially rebranding to enVVeno Medical Corporation in October 2021.
常规交易时段
US$7.86
−US$0.29 · -3.56%
盘中时间采用ET。市场数据可能有所延迟。
enVVeno Medical Corporation, based in Irvine, California, is a medical device firm founded in 1999 that is currently in its clinical development phase. The company's primary objective is to pioneer advanced bioprosthetic, tissue-engineered solutions intended to significantly elevate the existing standards of care for patients suffering from venous conditions. Their flagship product is the VenoValve, a specialized replacement venous valve developed for the management of chronic venous insufficiency. This device requires an open surgical procedure for implantation, which involves making a 5-to-6-inch incision in the patient's upper thigh to facilitate placement into the femoral vein. In addition to the VenoValve, enVVeno Medical is actively developing the enVVe system. This innovative system represents a non-surgical, transcatheter approach to venous valve replacement, comprising the enVVe valve itself, a dedicated delivery mechanism, and various supplementary accessories. The company previously operated under the name Hancock Jaffe Laboratories, Inc., before officially rebranding to enVVeno Medical Corporation in October 2021.
日内区间
当前US$7.86
52周区间
当前US$7.86
盘中时间采用ET。市场数据可能有所延迟。
enVVeno Medical Corporation, based in Irvine, California, is a medical device firm founded in 1999 that is currently in its clinical development phase. The company's primary objective is to pioneer advanced bioprosthetic, tissue-engineered solutions intended to significantly elevate the existing standards of care for patients suffering from venous conditions. Their flagship product is the VenoValve, a specialized replacement venous valve developed for the management of chronic venous insufficiency. This device requires an open surgical procedure for implantation, which involves making a 5-to-6-inch incision in the patient's upper thigh to facilitate placement into the femoral vein. In addition to the VenoValve, enVVeno Medical is actively developing the enVVe system. This innovative system represents a non-surgical, transcatheter approach to venous valve replacement, comprising the enVVe valve itself, a dedicated delivery mechanism, and various supplementary accessories. The company previously operated under the name Hancock Jaffe Laboratories, Inc., before officially rebranding to enVVeno Medical Corporation in October 2021.
日内区间
当前US$7.86
52周区间
当前US$7.86
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 销货成本 | — | 52.8万 USD | 54.6万 USD | 52.5万 USD | 45.29万 USD |
| 毛利 | — | −52.8万 USD | −54.6万 USD | −52.5万 USD | −45.29万 USD |
| 研究与开发 | 998.1万 USD | 1224.9万 USD | 1358.3万 USD | 991.4万 USD | 572.76万 USD |
| 销售、一般及管理费用 | 1091.8万 USD | 1104.9万 USD | 1110.9万 USD | 1449.3万 USD | 1071.19万 USD |
| 营业费用 | 2089.9万 USD | 2329.8万 USD | 2469.2万 USD | 2440.7万 USD | 1643.96万 USD |
| 利息收入 | 69.2万 USD | 38.9万 USD | 18万 USD | 16.1万 USD | 1.87万 USD |
| 折旧和摊销 | 48.9万 USD | 52.8万 USD | 54.6万 USD | 52.5万 USD | 45.3万 USD |
| 营业利润 | −2089.9万 USD | −2382.6万 USD | −2523.8万 USD | −2493.2万 USD | −1689.25万 USD |
| 净利润 | −1947.2万 USD | −2181.9万 USD | −2351.6万 USD | −2466.9万 USD | −1652.78万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2026年1月20日 | 1:35 | — | — |
股票拆分 | 2020年11月30日 | 1:25 | — | — |
已生效 2026年1月20日
1:35
已生效 2020年11月30日
1:25
报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
